MetLife, Inc. (MET) earnings on August 5, 2026
Prior outlook: Optimistic Outcome: Accurate
MetLife's stock rose after its earnings report, climbing as much as 4.7% and closing up nearly 4%. Strong profit results and a new $3 billion share buyback program boosted the price, even though sales came in below expectations.
MET price around the earnings
99.95
Change: +3.7%
2026-08-06, 20:00 UTC
Start of the measured window
End of the measured window
95.29
97.17
99.05
100.93
96.41
August 5, 2026
August 5, 2026
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- No trading (market closed)
- Starting price
Prior thesis
Prior outlook: Optimistic Outcome: Accurate
- Thesis published
- Results released
Strong past earnings and analyst upgrades, but very limited price target upside suggests a largely priced-in scenario.
Context analyzed before publication
- Trend
- Consistent run-up driven by strong past earnings and analyst upgrades, but limited price target upside suggests a priced
Analysts
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 1.94
- Analysts covering the stock
- 16
- Average price target
- 97.75
- Lowest price target
- 75
- Highest price target
- 106
- Upside to price target
- 1.3%
- Quarterly earnings growth
- 25.4%
- Revenue growth
- 2.7%
- Forward EPS
- 10.99
- Trailing EPS
- 5.18
- Analyst moves in the last 60 days
- 10
- Strong buy: 4
- Buy: 8
- Hold: 5
- Sell: 0
- Strong sell: 1
- Strong buy
- 4
- Buy
- 8
- Hold
- 5
- Sell
- 0
- Strong sell
- 1
- July 22, 2026 · TD Cowen: Maintains rating (Buy → Buy)
- July 21, 2026 · JP Morgan: Maintains rating (Overweight → Overweight)
- July 13, 2026 · Evercore ISI Group: Maintains rating (In-Line → In-Line)
- July 13, 2026 · Keefe, Bruyette & Woods: Maintains rating (Outperform → Outperform)
- July 10, 2026 · Jefferies: Maintains rating (Buy → Buy)
- July 9, 2026 · Wells Fargo: Maintains rating (Overweight → Overweight)
- July 9, 2026 · Mizuho: Maintains rating (Outperform → Outperform)
- July 8, 2026 · UBS: Maintains rating (Buy → Buy)
- July 7, 2026 · Barclays: Maintains rating (Overweight → Overweight)
- July 6, 2026 · Morgan Stanley: Maintains rating (Overweight → Overweight)
News and sentiment
Evidence
Sentiment
- Sentiment
- Cautious
- Mention volume
- High
- Normalized volume
- 99%
News
Sources (9)
- TD Cowen Maintains Buy on MetLife, Raises Price Target to $105 (opens in a new tab) — Benzinga
- JP Morgan Maintains Overweight on MetLife, Raises Price Target to $106 (opens in a new tab) — Benzinga
- Evercore ISI Group Maintains In-Line on MetLife, Raises Price Target to $103 (opens in a new tab) — Benzinga
- Keefe, Bruyette & Woods Maintains Outperform on MetLife, Raises Price Target to $105 (opens in a new tab) — Benzinga
- Jefferies Maintains Buy on MetLife, Raises Price Target to $103 (opens in a new tab) — Benzinga
- Wells Fargo Maintains Overweight on MetLife, Raises Price Target to $101 (opens in a new tab) — Benzinga
- Mizuho Maintains Outperform on MetLife, Raises Price Target to $102 (opens in a new tab) — Benzinga
- UBS Maintains Buy on MetLife, Raises Price Target to $105 (opens in a new tab) — Benzinga
- Barclays Maintains Overweight on MetLife, Raises Price Target to $94 (opens in a new tab) — Benzinga
Technicals
Evidence
- Price when the context was analyzed
- 96.19
- Average true range (ATR)
- 1.7%
- Distance to 52-week high
- -0.4%
- 14-day change (14d)
- +3.0%
- 30-day change (33d)
- +6.8%
- 30-day relative strength
- +3.3%
- SPY change (33d)
- +3.5%
- Nearest support
- 95.87
- Distance to nearest support
- 0.3%
- Nearest resistance
- 96.56
- Distance to nearest resistance
- 0.4%
- Volume accumulation ratio (14d / 46d)
- 1.06
- Mid: 95.87 (0.3% away, 0.2 ATR, 11 touches)
- Mid: 94.85 (1.4% away, 0.83 ATR, 9 touches)
- Mid: 94.16 (2.1% away, 1.27 ATR, 13 touches)
- Mid: 96.56 (0.4% away, 0.23 ATR, 9 touches)
- Mid: 97.58 (1.4% away, 0.86 ATR, 7 touches)
Trends
Evidence
- Average earnings surprise
- +2.1%
- May 6, 2026: actual EPS 2.42 vs estimate 2.27 (surprise +6.7%)
- February 4, 2026: actual EPS 2.49 vs estimate 2.34 (surprise +6.3%)
- November 5, 2025: actual EPS 2.37 vs estimate 2.32 (surprise +2.2%)
- August 6, 2025: actual EPS 2.02 vs estimate 2.16 (surprise -6.7%)
Expected move
- Implied move
- +1.7%
- Source
- Options chain
Reactions over its last 20 earnings
- Median move
- 2.1%
- 75th percentile move
- 3.4%
- 90th percentile move
- 5.7%
- Up / down moves
- 5 / 15
- Average up move
- +1.3%
- Average down move
- -3.0%
Monitoring and close
What MetLife, Inc. reported
- Status
- Finished
| Actual EPS | 2.43 |
|---|---|
| EPS estimate | 2.29 |
| EPS surprise | +6.1% |
| Revenue | $19,075 million |
| Revenue estimate | $19,709 million |
| Revenue surprise | -3.2% |
MetLife beat earnings expectations with $2.43 per share, but revenue fell short of estimates. Sentiment is optimistic on earnings, pessimistic on revenue.
Sources (2)
- MetLife beat earnings expectations with $2.43 per share, but revenue fell short of estimates. — Benzinga
- MetLife Q2 Adj. EPS $2.43 Beats $2.29 Estimate, Sales $19.075B Miss $19.709B Estimate (opens in a new tab) — Benzinga
Pre-market second reading after the results
- Verdict
- Beat expectations
Heading into the open, results beat expectations on earnings but not on revenue, and the price is indicating +1.8% pre-market, a move in line with the stock's usual reaction (about 2%). The figures confirm the optimistic scenario. In the 1,401 similar cases in our market history, the close held that direction 72% of the time.
How the stock reacted
- Outcome
- Accurate
- Consolidated
- +3.8%
- Max favorable move (MFE)
- 4.7%
- Max adverse move (MAE)
- 0.2%